HUE045864T2 - ST2L antagonisták és alkalmazási eljárások - Google Patents

ST2L antagonisták és alkalmazási eljárások

Info

Publication number
HUE045864T2
HUE045864T2 HUE13785158A HUE13785158A HUE045864T2 HU E045864 T2 HUE045864 T2 HU E045864T2 HU E13785158 A HUE13785158 A HU E13785158A HU E13785158 A HUE13785158 A HU E13785158A HU E045864 T2 HUE045864 T2 HU E045864T2
Authority
HU
Hungary
Prior art keywords
methods
st2l antagonists
st2l
antagonists
Prior art date
Application number
HUE13785158A
Other languages
English (en)
Inventor
Karen Duffy
Catherine Healy
Roberta Lamb
Ravi Malaviya
Michael Pratta
Natalie Fursov
Jinquan Luo
Michael Naso
Mark Tornetta
John Wheeler
Sheng-Jiun Wu
Leroy Hall
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HUE045864T2 publication Critical patent/HUE045864T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
HUE13785158A 2012-04-30 2013-04-29 ST2L antagonisták és alkalmazási eljárások HUE045864T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640407P 2012-04-30 2012-04-30
US201261640238P 2012-04-30 2012-04-30
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

Publications (1)

Publication Number Publication Date
HUE045864T2 true HUE045864T2 (hu) 2020-01-28

Family

ID=49477497

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13785158A HUE045864T2 (hu) 2012-04-30 2013-04-29 ST2L antagonisták és alkalmazási eljárások

Country Status (37)

Country Link
US (4) US9212227B2 (hu)
EP (2) EP2844292B1 (hu)
JP (3) JP6283354B2 (hu)
KR (2) KR20150008152A (hu)
CN (2) CN107098973A (hu)
AR (1) AR090909A1 (hu)
AU (2) AU2013256645B2 (hu)
BR (1) BR112014027165A2 (hu)
CA (1) CA2871948C (hu)
CL (1) CL2014002955A1 (hu)
CO (1) CO7240389A2 (hu)
CR (1) CR20140488A (hu)
CY (1) CY1122308T1 (hu)
DK (1) DK2844292T3 (hu)
EA (2) EA201891264A3 (hu)
EC (1) ECSP14025178A (hu)
ES (1) ES2755094T3 (hu)
HK (1) HK1208182A1 (hu)
HR (1) HRP20191884T1 (hu)
HU (1) HUE045864T2 (hu)
IL (2) IL235401B (hu)
LT (1) LT2844292T (hu)
MX (2) MX358134B (hu)
MY (1) MY166062A (hu)
NI (1) NI201400125A (hu)
NZ (3) NZ729913A (hu)
PE (1) PE20150641A1 (hu)
PH (2) PH12014502435A1 (hu)
PL (1) PL2844292T3 (hu)
PT (1) PT2844292T (hu)
RS (1) RS59511B1 (hu)
SG (2) SG10201608525SA (hu)
SI (1) SI2844292T1 (hu)
TW (3) TWI589588B (hu)
UA (1) UA118336C2 (hu)
UY (1) UY34774A (hu)
WO (1) WO2013165894A2 (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
RS55460B1 (sr) 2009-11-30 2017-04-28 Janssen Biotech Inc Mutirana fc antitela sa uklonjenom efektorskom funkcijom
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2968454B1 (en) 2013-03-15 2019-02-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
CA2946511C (en) 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3157634B1 (en) * 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2016140922A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
CN108026172B (zh) * 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
US20190016795A1 (en) * 2016-01-14 2019-01-17 Anaptysbio, Inc. Inhibition of allergic reaction using an il-33 inhibitor
US20190202907A1 (en) * 2016-09-02 2019-07-04 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
AU2018217816A1 (en) 2017-02-10 2019-08-15 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
KR102605045B1 (ko) 2017-04-13 2023-11-27 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
MX2020008291A (es) 2018-02-09 2020-09-25 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
KR20210084587A (ko) * 2018-10-31 2021-07-07 데리니아, 인크. 다가 조절 t 세포 조정제
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
CN114641494A (zh) 2019-11-04 2022-06-17 免疫医疗有限公司 抗-33治疗剂fpr治疗肾脏障碍
US20220380450A1 (en) 2019-11-04 2022-12-01 Medimmune Limited Methods of using il-33 antagonists
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
US11760797B2 (en) 2020-03-13 2023-09-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115867575A (zh) 2020-04-06 2023-03-28 免疫医疗有限公司 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
MX2022014243A (es) 2020-05-12 2022-12-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteina de union al antigeno st2.
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
TW202304965A (zh) * 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof
CN115838425B (zh) * 2022-08-31 2024-06-18 首都医科大学 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
EP1983044B1 (en) 1996-10-10 2016-08-10 Life Technologies Corporation Animal cell culture media comprising plant-derived nutrients
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2006055347A2 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
TWI454480B (zh) 2006-08-18 2014-10-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2069784A4 (en) * 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
RS55460B1 (sr) * 2009-11-30 2017-04-28 Janssen Biotech Inc Mutirana fc antitela sa uklonjenom efektorskom funkcijom
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
DK2552961T3 (en) 2010-03-30 2018-03-05 Janssen Biotech Inc HUMANIZED IL-25 ANTIBODIES
EP3434694B1 (en) 2010-04-09 2020-12-30 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
CN103097417B (zh) 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
EP3050899B1 (en) 2010-09-27 2019-09-04 Janssen Biotech, Inc. Antibodies binding human collagen ii
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TW201238976A (en) 2011-02-23 2012-10-01 Hoffmann La Roche Antibodies against human IL33R and uses thereof
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
EA201491996A1 (ru) 2015-04-30
AU2013256645A1 (en) 2014-11-13
TW201730216A (zh) 2017-09-01
US20170066831A1 (en) 2017-03-09
IL254569B (en) 2020-10-29
IL235401B (en) 2020-10-29
AU2013256645B2 (en) 2017-06-08
TW202019969A (zh) 2020-06-01
US20190062439A1 (en) 2019-02-28
TW201345923A (zh) 2013-11-16
JP2019162136A (ja) 2019-09-26
US20130336980A1 (en) 2013-12-19
IL254569A0 (en) 2017-11-30
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
PH12014502435A1 (en) 2015-01-12
MY166062A (en) 2018-05-22
NZ740221A (en) 2019-11-29
ECSP14025178A (es) 2015-08-31
KR20150008152A (ko) 2015-01-21
AR090909A1 (es) 2014-12-17
BR112014027165A2 (pt) 2017-07-18
US20130287777A1 (en) 2013-10-31
JP2018064560A (ja) 2018-04-26
MX2014013200A (es) 2014-12-08
TWI589588B (zh) 2017-07-01
EP3597219A1 (en) 2020-01-22
EA201891264A3 (ru) 2019-02-28
CO7240389A2 (es) 2015-04-17
UA118336C2 (uk) 2019-01-10
CA2871948A1 (en) 2013-11-07
NZ702136A (en) 2017-03-31
NI201400125A (es) 2016-11-30
WO2013165894A3 (en) 2014-03-27
UY34774A (es) 2013-11-29
TWI687440B (zh) 2020-03-11
JP6283354B2 (ja) 2018-02-21
EP2844292A2 (en) 2015-03-11
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
HK1208182A1 (en) 2016-02-26
CN104411333A (zh) 2015-03-11
AU2017202610B2 (en) 2019-06-13
NZ729913A (en) 2018-07-27
DK2844292T3 (da) 2019-10-21
WO2013165894A2 (en) 2013-11-07
CN104411333B (zh) 2017-04-26
EA031047B1 (ru) 2018-11-30
US9090694B2 (en) 2015-07-28
CR20140488A (es) 2015-01-12
HRP20191884T1 (hr) 2020-02-07
JP2015516817A (ja) 2015-06-18
SI2844292T1 (sl) 2020-02-28
SG11201407028WA (en) 2015-01-29
SG10201608525SA (en) 2016-12-29
EA201891264A2 (ru) 2018-11-30
US10450377B2 (en) 2019-10-22
CN107098973A (zh) 2017-08-29
CY1122308T1 (el) 2021-01-27
JP6622274B2 (ja) 2019-12-18
PL2844292T3 (pl) 2020-03-31
PE20150641A1 (es) 2015-05-11
LT2844292T (lt) 2019-11-25
ES2755094T3 (es) 2020-04-21
CA2871948C (en) 2020-09-08
IL235401A0 (en) 2014-12-31
KR20200037886A (ko) 2020-04-09
RS59511B1 (sr) 2019-12-31
US9951137B2 (en) 2018-04-24
PT2844292T (pt) 2019-11-26
KR102147140B1 (ko) 2020-08-25
TWI700299B (zh) 2020-08-01
AU2017202610A1 (en) 2017-05-11
EP2844292A4 (en) 2016-05-25
EP2844292B1 (en) 2019-08-21
AU2017202610B9 (en) 2019-06-20
CL2014002955A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
IL254569B (en) st2l antagonists and methods of use
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2928384A4 (en) ANCHORS CAPTURED BY THE FABRIC AND METHOD OF USE
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
GB201216649D0 (en) Agents and methods
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
GB201211775D0 (en) An electrode and use thereof
EP2909285A4 (en) GELIFYING AGENTS AND METHODS OF USE
PL2864417T3 (pl) Polimer i sposób zastosowania
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-